Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai’s Skyline Approved to Start US Trial of Gene Therapy for Macular Degeneration

publication date: Jul 7, 2023

Skyline Therapeutics, a Shanghai-Boston gene therapy company, was cleared to start a US Phase I/IIa trial of SKG0106, a one-time intravitreally delivered AAV gene therapy for neovascular age-related macular degeneration. The company develops candidates that address rare and severe diseases. Its expertise includes capsid discovery, vector engineering and design, in-vivo pharmacology, clinical development, analytical and process development along with CMC. Founded in 2019, Skyline has ten molecules in development. It plans to start a Global Phase I clinical trial of SKG0106 soon. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital